The Aggressiveness of African breast cancer: An expose’ on CD44+CD24-/low breast cancer stem cell

Eric Gyan (✉ mzxeg2@nottingham.ac.uk)  
University of Nottingham, School of Molecular Medical Sciences  https://orcid.org/0000-0001-5215-4421

Linda Ahenkorah-Fondjo  
Kwame Nkrumah University of Science and Technology, School of Medicine

William K.B.A Owiredu  
Kwame Nkrumah University of Science and Technology, School of Medicine

Andrew Jackson  
University of Nottingham, School of Molecular Medical Sciences, UK

Michael S. Toss  
University of Nottingham, School of Molecular Medical Sciences, UK

Patrick K. Akakpo  
University of Cape Coast, School of Medical Sciences

Leonard Derkyi-Kwarteng  
University of Cape Coast, School of Medical Science

Ganiyu A. Rahman  
University of Cape Coast, School of Medical Sciences

Andrew Green  
University of Nottingham, School of Molecular Medical Sciences

Research Article

Keywords: Breast cancer, CD44, CD24, Africans, prognosis, Immunohistochemistry

DOI: https://doi.org/10.21203/rs.3.rs-87095/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Breast cancer (BC) in Africans and people of African descent is generally aggressive, with poorer prognosis and worse clinical outcomes. The molecular basis of this is however not entirely understood. The CD44+/CD24−/low BC stem cell is known for its tumourigenic potential, tumour aggressiveness and its association with poor prognosis. This study identifies the relationship between CD44+/CD24−/low BC stem cells and clinicopathological features of breast cancer in an African population.

Methodology A Ghanaian BC cohort (n= 222) was used to assess CD44 and CD24 expression. Tissue microarray was constructed from the cohort samples and Immunohistochemically stained with CD44 and CD24 antibodies. The associations between clinicopathological features and the expression of the individual markers and their combinations were analysed.

Results Of the total 222 breast cancer samples, 81.9 % were cytoplasmic CD24 positive and were associated with higher tumour grade (OR-3.623; r=0.199; p=0.004), gender (OR-9.514; p=0.028), clinical prognostic grading (OR-2.357 r= 0.162; p=0.027) and Her2 positivity (OR-0.216; r=-0.155; p=0.026). CD44 was associated with higher tumour grade (OR-3.148; r= 0.145; p=0.037), and increased mitotic count (OR-3.043, r= 0.173; p=0.028). There was no association between CD44 expression and hormone receptor status. Together, CD44+/CD24−/low staining was associated with higher tumour grade (OR-3.162; r=0.166; p=0.018), gender (OR- 12.0; p=0.012), and higher clinical prognostic staging (OR- 2.888; r=0.186; p=0.011). An inverse association of CD44+CD24+ was found with tumour grade (OR-0.220; r=-0.246; p=0.000), mitotic count (OR-0.406; r=-0.190; p=0.017) and clinical prognostic staging (OR-0.486; r=-0.151; p=0.040). There was no association between CD44−CD24+ and all the clinicopathological features.

Conclusion Combined, CD44+CD24−/low was associated with poor prognosis and tumour aggression and may contribute to the tumour aggressiveness of African breast cancer. CD24 expression as a stand-alone marker was found to correlate with clinical and pathological indicators of tumour aggressiveness and poor prognosis.

Introduction

A plethora of data confirms the aggressiveness of breast cancers (BC) of African patients and of patients with African descent compared to their Caucasian counterparts. 1-3 The molecular basis for this disparity is however not fully understood. The expression of certain BC stem cells has however been suggested to be responsible for enhanced tumour aggressiveness. It is well established that breast cancers in Africans are more likely to be triple negative and basal like. 4-7 Racial disparity in cancer risk, prevalence and clinical outcomes have also been very well documented. 8-10 It is still unclear if breast cancer stem cells contribute to such racial disparity and to what extent they confer tumour aggressiveness remains largely unanswered. Knowledge on breast cancer stem cells in African breast cancers remains scanty.
Cancer stem cells are known to possess the intrinsic ability of self-renewal, have tumourigenic potential and drive tumour progression.\textsuperscript{11} They are also known to be responsible for chemotherapy resistance and tumour recurrence.\textsuperscript{12} The identification of these stem cells in tumours offers important evidences on tumorigenesis, therapeutic resistance and recurrence. These may also serve as important approaches for targeted therapies. Prognostication of tumours may also be based on presence or absence of specific cancer stem cells. Earlier studies have focused on elucidating the association that exists between cancer stem cells, prognostic markers, and response to adjuvant therapy. It has been reported that triple negativity and basal like phenotype (BLP) have poor prognosis and are associated with candidate stem cells CD44\textsuperscript{+} CD24\textsuperscript{-}.\textsuperscript{4,13,14} Since the discovery of CD44\textsuperscript{+}CD24\textsuperscript{-/low} phenotype breast stem cells with a tumourigenic potential by Al Hajj \textit{et al}, various studies continue to elucidate its role in breast cancer.\textsuperscript{11} Despite the intense research interest generated on this putative stem cell marker, its role remains puzzling. Do breast cancer stem cells contribute to such racial disparity and to what extent do they confer tumour aggressiveness? This study identifies the role of CD44\textsuperscript{+}CD24\textsuperscript{-/low} breast cancer stem cell marker in contributing to the inherent aggressiveness of African breast cancers.

**Materials And Methods**

This is a hospital based retrospective study of breast biopsies and reports of patients (n=222) presenting with breast cancer at the departments of pathology, Korle-Bu Teaching Hospital, Accra and the Cape Coast Teaching Hospital, Cape Coast, Ghana from 2012 to 2018. The Korle-Bu Teaching Hospital department of pathology is the largest in Ghana, receiving specimens from the Korle-Bu Teaching Hospital, the largest referral hospital in Ghana and from other health facilities within the Greater Accra Region. The department also receives specimen from all other regions of Ghana. The Cape Coast Teaching Hospital's pathology department also receives specimen from mainly the Central and Western regions of Ghana. Clinical and demographic data regarding age, gender, and clinical information were obtained from the histopathology request forms and registry. Histopathology slides of selected cases within the study period (2012-2018) were reviewed by two pathologists (PKA & LDK). Archival blocks of primary breast carcinoma from the Departments of Pathology, Korle-Bu and Cape Coast Teaching Hospitals were retrieved. Additional clinical information and histopathological features were obtained from the histopathology reports of patients. The information included the mean age of presentation, duration of symptoms, tumour grade, (based on mitotic count, nuclear grade, tubule formation). All cases were reviewed histopathologically and classified according to the recent WHO classification for breast tumours and histopathological grading done in accordance with the Nottingham criteria\textsuperscript{15}.

**Tissue Microarray (TMA) Construction**

Archival formalin fixed paraffin embedded (FFPE) blocks’ and Hematoxylin and Eosin (H&E) stained slides were reviewed and areas of tumour selected. Areas of normal tissue, necrosis, and haemorrhage were ignored. Three cores 1mm each (2 peripheral tumour and 1 central) were punched out from the
representative selected areas and arrayed into a new recipient paraffin block using TMA Grand Master® (3D HISTECH®, Budapest, Hungary). Four micrometre thickness of TMA sections were cut and mounted on Superfrost slides.

**Immunohistochemistry (IHC)**

TMA were stained using CD24 Monoclonal antibody (SN3), Thermofisher and CD44 monoclonal antibodies (156-3C11), Thermofisher at dilutions of 1:200 and 1:750 respectively. Immunohistochemical antibody labelling was done using the NOVOLINK polymer detection system. To enhance tissue adhesion to the slide, tissue microarrays were pre-heated at 60°C on a hot plate for 20 minutes and cooled. Deparaffinisation was done on tissue sections in xylene and rehydrated through a series of graded alcohols and rinsed in distilled water. Antigen retrieval was enhanced by boiling slides in citrate buffer (27ml of citrate in 123 ml disodium citrate and made up to 1.5L with ddH2O) at pH-6.0 and microwaved at full power for 20 minutes. Endogenous peroxidase activity was blocked using the Peroxidase blocking reagent from the NOVOLINK® kit for 5 minutes and rinsed with PBS for 15 minutes. Protein blocking was done for 5 minutes to minimize nonspecific binding and rinsed thoroughly with PBS for 15 minutes. Primary antibodies were added in the following dilutions: CD24- 1:200 and CD44- 1:750 and incubated in a black box for 1 hour at room temperature. A thorough rinse was done for 15 minutes with PBS tween and then incubated with Post Primary Novolink reagent for 30 minutes in a black box. After a 15-minute thorough rinse, a Polymer was added and incubated for 30 minutes. Peroxidase was then developed by incubating 3,3'-diaminobenzidine chromogen solution (DAB) made up to in 1:20 dilution with DAB substrate buffer and incubated for 5 minutes. Counter staining with hematoxylin was done and incubated for 6 minutes. Dehydration and clearing were done using the Leica autostainer. Sections were then mounted with DPX. Breast cancer cases known to be positive for the markers being studied were used as positive controls. Evaluation of staining was done for both markers.

The semi-quantitative H scoring system was employed in scoring. The intensity of CD24 and CD44 expression were scored as 0 (no expression), 1 (weak), 2 (moderate) and 3 (strong). The total score was calculated as the percentage of positive cells multiplied by the intensity giving a range of 0-300. A cut point of ≤40% score was designated as negative and >40% as positive in keeping with Ahmed et al’s study\(^1\).\(^6\)

For Oestrogen and Progesterone receptor staining, positive expression was considered as nuclear immunoreactivity in ≥1% of neoplastic cells. HER2 was analyzed at the time of diagnosis according to the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) protocols\(^1\).\(^7\)

The molecular subtypes were classified as Luminal A (ER+ and/or PR+ and Her2-), Luminal B (ER+ and/or PR+ and Her2+), Triple Negative (ER- PR- and Her2-) and Her2+ (ER- PR- and Her2+)\(^1\).\(^7\).

**Statistical Analysis**
IBM SPSS version 24.0 package program (SPSS inc., Chicago, IL, USA) was used in the statistical analysis. The association between the markers and clinicopathological features were done with cross tables using chi-square test and odd ratios. Correlations were done with Pearson's correlation test. Statistical significance was put at the $\alpha$ level.

**Results**

A total of 222 breast carcinoma samples were used in the study. The study population were predominantly females with 219/222 (98.6%) being females and 3/222 (1.4%) males. The mean age of patients presenting with breast carcinoma in the cohort was 51.4 ±12.5. A total of 110 (49.5%) involved the right breast, while 107(48.2%) involved the left breast and only 1(0.5) were bilateral. There was no indication of laterality in 4 of the patients. Of the total, 177(79.7%) presented with solitary masses and 41(18.5%) with multiple masses with 4 missing data. Table 1 shows details of clinicopathological features of patients.

Table 1: Clinicopathological features of patients
| Parameter                          | Frequency (%) |
|-----------------------------------|---------------|
| **Age (n=220)***                  |               |
| <50                               | 108 (49.1%)   |
| ≥50                               | 112 (50.9%)   |
| **Grade (n=212)***                |               |
| I                                 | 24 (11.3%)    |
| II                                | 84 (39.6%)    |
| III                               | 104 (49.1%)   |
| **Clinical prognostic staging (n=188)*** |       |
| IA                                | 3 (1.6%)      |
| IB                                | 9 (4.8%)      |
| IIA                               | 28 (14.9%)    |
| IIB                               | 27 (14.4%)    |
| IIIA                              | 25 (13.3%)    |
| IIIB                              | 48 (25.5%)    |
| IIIC                              | 48 (25.5%)    |
| **Nottingham Prog. Index (n=113)*** |         |
| Good NPI (<3.4)                   | 3 (2.7%)      |
| Moderate NPI (3.41-5.4)           | 30 (26.5%)    |
| Poor NPI (>/=5.41)                | 80 (70.8%)    |
| **Lymph Node Stage(n=113)***      |               |
| 1 (Negative)                      | 26 (23.0%)    |
| 2 (1-3 LN involved)               | 31 (27.4%)    |
| 3 (> 3 LN involved)               | 56 (49.6%)    |
| **Vascular Invasion (n=177)***    |               |
| Yes                               | 118 (66.7%)   |
| No                                | 59 (33.3%)    |
| **Mitosis(n=164)***               |               |
| <10                               | 58 (35.4%)    |
| Tumour size, cm (n=196)* |       |
|--------------------------|-------|
| ≤2                       | 15(7.7%) |
| >2-<5                    | 63(32.1%) |
| ≥5                       | 118 (60.2%) |

| Molecular subtypes (n=212)* |       |
|-----------------------------|-------|
| Luminal A                   | 75 (35.4%) |
| Luminal B                   | 21 (9.9%) |
| Her2                        | 22 (10.4%) |
| Triple Negative             | 94 (44.3%) |

*missing data

**Clinicopathological correlations**

There was no significant association between age and the clinicopathological features. Apart from clinical prognostic stage ($p<0.001$), Nottingham Prognostic Index ($p<0.001$) and Mitosis count ($p<0.001$) which had significant association with tumour grade, all other clinicopathological parameters did not show any association. Clinical prognostic stage also showed significant association with all clinicopathological parameters (Grade $p<0.001$; NPI $p=0.004$; tumour size $p<0.001$; vascular invasion $p<0.001$; mitotic count $p<0.001$) except for weight and age.

**Immunohistochemistry analysis**

Of the total, 71(32.6%) and 74(33.8%) of patients expressed estrogen and progesterone receptors respectively. 38 (18.3%) patients expressed Her2 receptor. 94 (44.3%) were negative for all 3 receptors hence were triple negative.

**Cytoplasmic CD24 expression and its association with clinicopathological features**

Eighty-one-point one percent of tumours were cytoplasmic CD24 positive. Tumour grade ($p=0.004$) and clinical prognostic staging ($p=0.027$) were the only clinicopathological features which had significant association with CD24 cytoplasmic expression. Age did not have an association with CD24 cytoplasmic
expression (OR-1.9, \(p=0.064\)). Grade 2 & 3 tumours had higher CD24 cytoplasmic expression with between 3 to 4-fold increase (OR-3.6, \(p=0.004\)). Females predominantly had higher CD24 cytoplasmic expression (OR-9.5, \(p=0.028\)). Although marginally non-significant (\(p=0.085\)), it appeared tumours with >10 mitotic features per 10 high power field (/10hpf) had a 2-fold increased CD24 cytoplasmic expression compared with tumours <10/10hpf from the odd ratio. Clinical Prognostic staging (stage III and above) was associated with about 2-fold increased cytoplasmic CD24 expression compared with stage I&II tumours (OR-2.3, \(p=0.027\)). Table 2 summarises the cytoplasmic expression of CD24 and its association with clinicopathological features. Figure 1 shows membranous staining of CD44 and homogenous cytoplasmic staining of CD24

Table 2: CD24 Cytoplasmic expression and its relationship with clinicopathological features
| Parameters                  | CD24 Cytoplasmic expression | Significance  |
|-----------------------------|-----------------------------|---------------|
|                             | Negative(%) | Positive(%) | r             | OR     | p value     |
|                             |             |             | (95%CI)       |        |             |
| Patient’s age               |             |             |               |        |             |
| <50                         | 24(61.5)    | 79(45.1)    | 0.127         | 1.9    | 0.064       |
| ≥50                         | 15(38.4)    | 96(54.9)    | 0.0127        | 1.9    | 0.064       |
| Grade                       |             |             |               |        |             |
| 1                           | 9(37.5)     | 15(62.5)    | 0.199         | 3.623  | 0.004*      |
| 2/3                         | 26(14.2)    | 157(85.8)   | 0.199         | 3.623  | 0.004*      |
| Tumour size                 |             |             |               |        |             |
| ≤2                          | 4(26.7)     | 11(73.3)    | 0.068         | 1.782  | 0.344       |
| >2                          | 30(16.9)    | 147(83.1)   | 0.068         | 1.782  | 0.344       |
| Vascular Invasion           |             |             |               |        |             |
| Yes                         | 19(16.8)    | 94(83.2)    | 0.039         | 1.263  | 0.608       |
| No                          | 8(13.8)     | 50(86.2)    | 0.039         | 1.263  | 0.608       |
| LN stage                    |             |             |               |        |             |
| Negative                    | 5 (19.2)    | 21(80.8)    | 0.058         | 1.429(0.452-4.516) | 0.542 |
| Positive                    | 12(14.3)    | 72(85.7)    | 0.058         | 1.429(0.452-4.516) | 0.542 |
| Mitosis                     |             |             |               |        |             |
| ≤10                         | 14(24.6)    | 43(74.5)    | 0.0136        | 2.047  | 0.085       |
| >10                         | 14(13.7)    | 88(86.3)    | 0.0136        | 2.047  | 0.085       |
| NPI                         |             |             |               |        |             |
| Mod. To Good NPI (<3.4-5.4) | 2(18.2)     | 27(81.8)    | 0.035         | 1.222  | 0.715       |
| Poor NPI (>/=5.41)          | 12(15.4)    | 66(84.6)    | 0.035         | 1.222  | 0.715       |
| Clinical Prognostic Staging | I&II | II | III |
|----------------------------|------|----|-----|
|                            | 17(25.4) | 50(74.6) | 0.162 |
|                            | 15(12.6)  | 104(87.4)  | 2.357(1.089-5.101)  | 0.027* |

*statistically significant p value at 95% CI, OR- Odd Ratio, r- Pearson's correlation coefficient, NPI- Nottingham Prognostic Index

**Cytoplasmic CD24 expression and hormone receptor markers**

Table 3 indicates the cytoplasmic CD24 expression pattern in relation to hormone receptor status. Only Her2 had a significant association with CD24 cytoplasmic expression. Her2 negative tumours had 5 times higher CD24 expression in comparison with Her2 positive tumours (OR-4.626, p=0.026). There was no association between the molecular subtypes and CD24 expression (Table 3).

Table 3: Association between CD24 expression, Hormone receptor status and Her2 status
| Marker | CD24 cytoplasmic expression | Significance |
|--------|-----------------------------|--------------|
|        | Negative(%) (95%CI) | Positive(%) | OR | r Value | P |
| ER     | Positive | 13(18.6) | 57(81.4) | 1.076 (0.513-2.295) | 0.013 | 0.845 |
|        | Negative | 25(17.5) | 118(82.5) |  |  |  |
| PR     | Positive | 13(17.6) | 61(82.4) | 0.943 (0.452-1.965) | 0.011 | 0.875 |
|        | Negative | 26(18.4) | 115(81.6) |  |  |  |
| Her2   | Positive | 2(5.3) | 36(94.7) | 0.216 (0.049-0.941) | -0.155 | 0.026* |
|        | Negative | 34(20.5) | 132(79.5) |  |  |  |
| Subtypes | Triple Neg | 16(17.6) | 75(82.4) | 1.035 (0.502-2.132) | 0.006 | 0.926 |
|        | Others | 20(17.1) | 97(82.9) |  |  |  |
| Molecular subtypes | Luminal A | 16(21.6) | 58(78.4) | 1.572(0.758-3.261) | 0.222 |  |
|        | Luminal B | 2(9.1) | 20(90.9) | 0.447(0.100-2.004) | 0.281 |  |
|        | Her2+ | 2(9.1) | 20(90.9) | 0.447(0.100-2.004) | 0.281 |  |
|        | Triple Negative | 16(17.6) | 75(82.4) | 1.035(0.502-2.132) | 0.926 |  |

*statistically significant p value at 95% CI, OR- Odd Ratio, r- Pearson's correlation coefficient, ER- Estrogen receptor, PR- Progesterone receptor
Table 4: Association between CD44 and clinicopathological features
| Parameters          | CD44 Cytoplasmic expression | Significance |
|--------------------|-----------------------------|--------------|
|                    | Negative(%) | Positive(%) | OR (95%CI)    | r   | p   |
| **Patient's age**  |               |             |               |     |     |
| <50                | 10(47.6)     | 95(49.0)    | 0.947 (0.38-2.33) | -0.008 | 0.906 |
| ≥50                | 11(52.4)     | 99(51.0)    |               |     |     |
| **Grade**          |               |             |               |     |     |
| 1                  | 5(25.0)      | 18(9.6)     | 3.148(1.027-9.674) | 0.145 | 0    |
| 2&3                | 15(75.0)     | 170(90.4)   |               |     | 0.037* |
| **Tumour size**    |               |             |               |     |     |
| ≤2                 | 1(5.0)       | 14(8.2)     | 0.590 (0.073-4.743) | -0.036 | 0.616 |
| >2                 | 19(95.0)     | 157(91.8)   |               |     |     |
| **Vascular Invasion** |           |             |               |     |     |
| Yes                | 15(78.9)     | 100(65.4)   | 1.988 (0.628-6.290) | 0.090 | 0.235 |
| No                 | 4(21.1)      | 53(34.6)    |               |     |     |
| **LN stage**       |               |             |               |     |     |
| Negative           | 4(36.4)      | 22(22.4)    | 1.974 (0.529-7.367) | 0.098 | 0.305 |
| Positive           | 7(63.6)      | 76(77.6)    |               |     |     |
| **Mitosis**        |               |             |               |     |     |
| ≤10                | 10(58.8)     | 46(31.9)    | 3.043 (1.089-8.503) | 0.173 | 0.028* |
| >10                | 7(41.2)      | 98(68.1)    |               |     |     |
| **NPI**            |               |             |               |     |     |
| Mod. to Good NPI (<5.41) | 6(54.5)   | 26(26.3)    | 3.369 (0.948-11.978) | 0.187 | 0.050 |
| Poor NPI (>/=5.41) | 5(45.5)      | 73(73.7)    |               |     |     |
| Triple Negative status |  |  |
|------------------------|----------|----------|-----------------|--------|----------|---------|
| Triple Negative        | 8(8.5)   | 86(91.5) | 0.814(0.318-2.081) | 0.667  |
| Others                 | 12(10.3) | 105(89.7) | -0.030          |        |

| Clinical Prognostic Staging |  |  |
|-----------------------------|----------|----------|-----------------|--------|----------|---------|
| I & II                      | 6(9.1)   | 60(90.9) | 0.831(0.300-2.298) | 0.721  |
| III                         | 13(10.7) | 108(89.3) | -0.026          |        |

*statistically significant p value at 95% CI, OR- Odd Ratio, r- Pearson's correlation, NPI-Nottingham Prognostic index

**CD24 nuclear staining**

CD24 nuclear staining of 14% (30/212) was recorded in this study but did not have an association with any of the clinicopathological features and hormone receptor status.

**Association between CD44 expression and clinicopathological features**

Tumour grade and mitotic count per high power field were the only clinicopathological parameters significantly associated with CD44 expression. CD44 expression had a 3-fold increase in grades (2&3) tumours (OR-3.148, 95%CI 1.027-9.674, \( p=0.037 \)). Similarly, a mitotic count > 10/10hpf was found to be associated with higher CD44 cytoplasmic positivity (3-fold increased odds) (OR-3.043 95%CI-1.089-8.503, \( p=0.028 \)). Table 4 summarises the association between CD44 cytoplasmic expression and clinicopathological features.

**Association between CD44 cytoplasmic expression and hormone receptor status**

This study revealed no association between CD44 cytoplasmic expression and ER, PR & Her2 status. A summary of CD44 cytoplasmic expression and hormonal status can be found in table 5. Triple negative tumours predominantly expressed CD44 (45%).
Table 5: Association and correlation between cytoplasmic expression of CD44 and hormone receptor status

| Marker     | CD44 cytoplasmic expression | Significance |
|------------|-----------------------------|--------------|
|            | Negative (%) | Positive (%) | OR (95%CI) | r | p value     |
| ER         |               |              |            |   |             |
| Positive   | 9 (42.9)     | 61 (31.3)    | 1.0        | 0.073 | 0.282     |
| Negative   | 12 (57.1)    | 134 (68.7)   | 1.648 (0.659-4.117) |   |             |
| PR         |               |              |            |   |             |
| Positive   | 8 (38.1)     | 64 (32.7)    | 1.0        | 0.034 | 0.615     |
| Negative   | 13 (61.9)    | 132 (67.3)   | 1.269 (0.501-3.217) |   |             |
| Her2       |               |              |            |   |             |
| Positive   | 4 (20.0)     | 34 (18.3)    | 1.0        |     | 0.850     |
| Negative   | 16 (80.0)    | 152 (81.7)   | 1.118 (0.351-3.555) |   |             |
| Molecular Subtypes |   |              |            |   |             |
| Luminal A  | 8 (40)       | 66 (34.6)    | 1.0        |     | 0.695     |
| Luminal B  | 3 (15)       | 18 (9.4)     | 0.727 (1.175-3.026) | -0.030 |             |
| Her2+      | 1 (5)        | 21 (11.0)    | 2.545 (0.301-21.550) |   |             |
| Triple Neg | 8 (40)       | 86 (45.0)    | 1.303 (0.465-3.654) |   |             |

*statistically significant p value at 95% CI, OR- Odd Ratio, r- Pearson's correlation

**CD44/CD24 combined phenotypes**

Predominantly, CD44⁺CD24⁺ was the most occurring combined phenotype (76%) with CD44⁺CD24⁻ as the second most common phenotype (15%). CD44⁻CD24⁻ (3%) was however the least occurring phenotype Fig. 2.
Association between CD44/CD24 combined phenotypes and clinicopathological features

Figure 3 shows the various combinations of CD44 and CD24 using same cases as reference.

**CD44⁺CD24⁻/low**

CD44⁺CD24⁻/low was found to be significantly associated with tumour grade (OR-3.1, *p*=0.018), gender (*p*=0.012), and clinical prognostic staging (OR-2.8, *p*=0.011). In relation to age, a trend of CD44⁺CD24⁻/low appeared to be predominant in the patients <50 years old although marginally non-significant (OR 2.0, *p*=0.072). Tumours with higher grades (grade 2&3) expressed more CD44⁺CD24⁻/low (OR-3.1, *p*=0.018). Females have 12-fold increased risk of expressing CD44⁺CD24⁻/low compared with males (*p*=0.012). CD44⁺CD24⁻/low has almost a 3-fold increased cytoplasmic expression in clinical prognostic stage III compared with lower stages I&II (*p*=0.011, OR- 2.9)

**CD44⁺CD24⁺**

Significant association of CD44⁺CD24⁺ was found with tumour grade (*p*<0.001 *r*=-0.246), mitotic count (*p*=0.017 *r*=-0.190) and clinical prognostic staging (*p*=0.040 *r*=-0.151). Higher grade tumours (2&3) expressed less of CD44⁺CD24⁺ phenotype compared to the low grade tumours (OR-0.220, *p*<0.001). Less CD44⁺CD24⁺ expression was seen in the older age group (≥ 50years) (OR 0.689, *p*=0.248). The odds of larger tumours (>2cm) expressing CD44⁺CD24⁺ phenotype was lesser (OR- 0.617, *p*=0.398 *r*=-0.062) likewise the odds of females presenting with this phenotype lesser than males (OR- 0.152 *p*=0.081).

Tumours with <10 mitotic counts/10hpf expressed more CD44⁺CD24⁺ phenotypes compared to ≥10 mitotic counts/10hpf (OR-2.46 *p*= 0.017). Clinical prognostic staging III tumours presented with less CD44⁺CD24⁺ phenotypic expression (OR-0.486, *p*=0.040, *r*=-0.151).

**CD44⁻CD24⁻/low**

CD44⁻CD24⁻/low is significantly associated with mitotic count (*p*=0.011 *r*=0.202) and Nottingham Prognostic Index (NPI) (*p*=0.041 *r*=0.196). The odds of expression of CD44⁻CD24⁻/low is about 10 times higher in tumours with increased mitotic counts (≥10/10hpf). The expression of CD44⁻CD24⁻/low corresponded with increasing NPI (OR-7.86 *p*=0.041)
There is no association between CD44-CD24+ and all the clinicopathological features. Table 6 summarises the CD44CD24 combinatorial phenotypes with clinicopathological features.

Table 6: Association between CD44/CD24 combination phenotypes and clinicopathological features
| Parameter                  | %CD44+CD24- | %ofCD44+CD24+ | %ofCD44-CD24- | %ofCD44-CD24+ |
|---------------------------|-------------|---------------|---------------|---------------|
| **Age**                   |             |               |               |               |
| <50 (n=101)               | 62.5(n=20)  | 45.6(n=73)    | 57.1(n=4)     | 33.3(n=4)     |
| ≥50 (n=110)               | 37.5(n=12)  | 54.4(n=87)    | 42.9(n=3)     | 66.7(n=8)     |
| OR                        | 2.016(0.930-4.372) | 0.689(0.366-1.298) | 1.471(0.321-6.738) | 0.526(0.153-1.806) |
| *p*                       | 0.072       | 0.248         | 0.617         | 0.299         |
| **Grade**                 |             |               |               |               |
| 1(n=23)                   | 24.1(n=7)   | 7.0(n=11)     | 33.3(n=2)     | 25.0(n=3)     |
| 2&3 (n=192)               | 75.9 (n=22) | 93.0(n=157)   | 66.7(n=4)     | 75.0(n=9)     |
| OR                        | 3.162(1.170-8.542) | 0.220(0.09-0.539) | 4.214(4.727-24.41) | 2.867(0.717-11.466) |
| *p*                       | 0.018*      | 0.000*        | 0.083         | 0.121         |
| **Tumour size (cm)**      |             |               |               |               |
| ≤2(n=15)                  | 14.3(n=4)   | 7.0(n=10)     | 0.0(n=0)      | 8.3(n=1)      |
| >2(n=174)                 | 85.7(n=24)  | 93.0(n=133)   | 100.0(n=6)    | 91.7(n=11)    |
| OR                        | 2.273(0.669-7.720) | 0.617(0.199-1.907) | 4.65(0.127-8.806) | 0.958         |
| *p*                       | 0.178       | 0.398         | 0.465         | 0.958         |
| **Gender**                |             |               |               |               |
| Male(n=3)                 | 6.3(n=2)    | 0.6(n=1)      | 0.0(n=0)      | 0.0(n=0)      |
| Female(n=210)             | 93.8(n=30)  | 99.4(n=161)   | 100.0(n=7)    | 100(n=12)     |
| OR                        | 12.00(1.055-136.49) | 0.152(0.014-1.714) | 0.748         | 0.670         |
| *p*                       | 0.012*      | 0.081         | 0.748         | 0.670         |
| **Vascular Invasion**     |             |               |               |               |
| Present (n=112)           | 70.0 (n=14) | 64.9(n=85)    | 71.4(n=5)     | 80.0(n=8)     |
| Absent (n=56)             | 30.0 (n=6)  | 35.1(n=46)    | 28.6(n=2)     | 20.0(n=2)     |
| OR                        | 1.190(0.431-3.286) | 0.684(0.305-1.537) | 1.262(0.237-6.717) | 2.077(0.426-10.124) |
| *p*                       | 0.736       | 0.357         | 0.785         | 0.356         |
| **Lymph Node stage**      |             |               |               |               |
| Negative(n=26)            | 23.1(n=3)   | 22.4(n=19)    | 50.0(n=2)     | 33.3(n=2)     |
| Positive (n=82)           | 76.9(n=10)  | 77.6(n=66)    | 50.0(n=2)     | 66.7(n=4)     |
| OR                        | 0.939 (0.238-3.707) | 0.658(0.236-1.833) | 3.333(0.446-24.93) | 1.625         |
| *p*                       | 0.929       | 0.421         | 0.216         | 0.585         |
| **Mitosis**               |             |               |               |               |
| ≤10(n=55)                 | 40.9(n=9)   | 30.0(n=36)    | 83.3(n=5)     | 55.6(n=5)     |
| >10(n=102)                | 59.1(n=13)  | 70.0(n=84)    | 16.7(n=1)     | 44.4(n=4)     |
|                              | OR      | p       | OR      | p       | OR      | p       |
|------------------------------|---------|---------|---------|---------|---------|---------|
|                              |         | (0.533-3.366) | (0.191-0.863) | (1.149-88.77) | (0.630-9.528) |
|                              | 1.339   | 0.533   | 0.406   | 0.017*  | 10.100  | 0.011*  |
|                              |         |         |         |         |         |         |
| **Nottingham Prognostic Index** |         |         |         |         |         |         |
| <3.4-5.4 (n=32)              | 21.4 (n=3) | 27.1 (n=23) | 75.0 (n=3) | 50.0 (n=3) |
| >5.4 (n=77)                  | 78.6 (n=11) | 72.9 (n=62) | 25.0 (n=1) | 50.0 (n=3) |
|                              | 0.621 (0.161-2.392) | 0.618 (0.238-1.607) | 7.862 (0.786-78.673) | 2.552 (0.487-13.379) |
|                              | 0.485   | 0.321   | 0.041*  | 0.253   |
| **Triple Negative status**   |         |         |         |         |         |         |
| Present (n=91)               | 44.8 (n=13) | 45.0 (n=72) | 42.9 (n=3) | 27.3 (n=3) |
| Absent (n=116)               | 55.2 (n=16) | 55.0 (n=88) | 57.1 (n=4) | 72.7 (n=8) |
|                              | 1.042 (0.473-2.294) | 1.206 (0.623-2.334) | 0.955 (0.208-4.376) | 0.460 (0.119-1.787) |
|                              | 0.919   | 0.579   | 0.952   | 0.252   |
| **Clinical prognostic staging** |         |         |         |         |         |         |
| I & II (n=66)                | 22.7 (n=15) | 68.2 (n=45) | 3.0 (n=2) | 6.1 (n=4) |
| III (n=198)                  | 77.3 (n=51) | 31.8 (n=21) | 97.0 (n=64) | 93.9 (n=62) |
|                              | 2.888 (1.239-6.731) | 0.486 (0.243-0.973) | 0.898 (0.160-5.041) | 1.032 (0.291-3.665) |
|                              | 0.011*  | 0.040*  | 0.903   | 0.961   |

*statistically significant p value at 95% CI, OR- Odd Ratio

**Association between CD44/CD24 combined phenotypic expression and hormonal status**

No significant association is realised between CD44/CD24 combined phenotypes and hormonal status (Table 7).

Table 7: The association between CD44/CD24 combined phenotypic expression and hormonal status
## Combinatorial phenotypes expression

| Marker | CD44-/CD24- | CD44+/CD24+/low | CD44+/CD24+ | CD44-/CD24+ |
|--------|-------------|-----------------|-------------|-------------|
| ER     |             |                 |             |             |
| Positive | 3(42.9)    | 10(32.3)        | 50(30.9)    | 6(50.0)     |
| Negative | 4(57.1)    | 21(67.7)        | 112(69.1)   | 6(50.0)     |
| OR     | 1.580(0.344-7.261) | 0.985(0.436-2.224) | 0.728(0.376-1.411) | 2.175(0.675-7.008) |
| p value | 0.554       | 0.970           | 0.376       | 0.184       |
| PR     |             |                 |             |             |
| Positive | 3(42.9)    | 10(31.3)        | 54(33.3)    | 5(41.7)     |
| Negative | 4(57.1)    | 22(68.8)        | 108(66.7)   | 7(58.3)     |
| OR     | 1.489(0.324-6.840) | 0.917(0.473-1.775) | 0.872(0.389-1.957) | 1.429(0.473-4.670) |
| p value | 0.607       | 0.796           | 0.741       | 0.553       |
| Her2   |             |                 |             |             |
| Positive | 0(0.0)     | 2(6.9)          | 32(20.6)    | 4(36.4)     |
| Negative | 7(100)     | 27(93.1)        | 123(79.4)   | 7(63.6)     |
| OR     | 0.282(0.064-1.241) | 1.778(0.694-4.555) | 2.639(0.731-9.521) |             |
| p value | 0.195       | 0.076           | 0.226       | 0.126       |
| Subtypes |           |                 |             |             |
| Luminal A | 4(57.1)    | 12(41.4)        | 53(33.1)    | 4(36.4)     |
| Luminal B | 0(0.0)     | 2(6.9)          | 16(10.0)    | 3(27.3)     |
| Her2+   | 0(0.0)     | 2(6.9)          | 19(11.9)    | 1(9.1)      |
| Triple Neg | 3(42.9)    | 13(44.8)        | 72(45.0)    | 3(27.3)     |

*statistically significant p value at 95% CI, OR- Odd Ratio, ER- Estrogen Receptor, PR- Progesterone receptor
Discussion

Since the tumourigenicity of breast cancer stem cells (BCSC) was first demonstrated by Al-Haji et al in 2003\textsuperscript{11}, population based comparative ethnic and racial studies comparing the expression pattern of BCSC in different ethnic groups and races remain scanty. Although research evidence on cancer stem cells (CSC) are accumulating on Caucasian and Asian breast cancer populations, studies in African populations remain at the lowest ebb. There is well-documented evidence of racial difference of cancer risk, prevalence and clinical outcome\textsuperscript{8-10} with breast cancers of Africans and those of African descent presenting with relatively aggressive tumours\textsuperscript{18}. A constellation of research evidence points to increased triple negative breast cancer in Africans\textsuperscript{4-6}.

In keeping with literature\textsuperscript{1-3}, tumours from our cohort (African population) were aggressive as evidence by patients presenting with higher clinical prognostic stage (about 6 out of 10 having a clinical prognostic stage of III), higher tumour grade (9 out of 10 with tumour grade of II and above) and poor NPI (about 70% with NPI>5.4). Furthermore, over 90% of the tumours were >2cm in size with a total lymph node involvement of 77% at the time of presentation. The tumours also had a very high triple negative prevalence (44.3%) consistent with previous studies in African populations\textsuperscript{4-7}. To answer the question of whether breast cancer stem cells contribute to the inherent tumour aggressiveness in this cohort, we sort to find out the expression pattern of one of the well characterized breast cancer stem cell markers CD44\textsuperscript{+}CD24\textsuperscript{-/low} across our cohort. The clinicopathological association of the expression of the individual markers (CD44 and CD24) as well as their combined phenotypes were studied.

We found a high cytoplasmic CD24 expression associated with tumour aggressiveness and poor prognosis comparable to earlier studies\textsuperscript{16,19}. A high prevalence of CD24\textsuperscript{+} tumours (about 80%) was recorded with significant associations with tumour grade, clinical prognostic staging and Her2 status in this study. However, Kapucuoglu \textit{et al} found no association between the clinicopathological parameters and either CD24 and CD44 in a study involving 105 invasive ductal carcinoma samples\textsuperscript{20}. Tumours without Her2 receptor amplification had between 4-5-fold increase in CD24 expression compared with tumours with positive Her2 receptor status in contradiction with the findings of Ahmed \textit{et al}\textsuperscript{16}. Their study rather reported a positive association with the reason for such discrepancy unknown. Although there was no significant association between lymph node involvement, mitotic count, Nottingham prognostic Index and Triple negative status, we realised a 1-2 fold increased expression of CD24 in tumours with lymph node involvement, a 2 fold increase in tumours with \geq 10 mitotic counts per high power field and between 1 -2 fold increase in tumours with poorer NPI (>5.41). Triple negative tumours had a slightly increase in CD24 expression compared with other molecular subtypes although statistically not significant, a trend similar to Ahmed \textit{et al} who had significant association between CD24 negative tumours and luminal subtypes as well as CD24 positive tumours with triple negative subtypes\textsuperscript{16}.

The high expression of CD24 in our cohort coupled with its association with tumour aggressiveness and poor prognosis makes it possibly an important target for immunotherapy. Although there was a comparable CD24 nuclear staining with Ahmed \textit{et al}'s study (14% vs 14.5%) our cohort did not show any
significant association with the clinicopathological parameters in contradiction to Ahmed et al/ who recorded associations with tumour size, grade and lobular type tumour.\textsuperscript{16}

Similar to the cytoplasmic CD24 expression, tumour grade and mitotic count were the only features significantly associated with CD44 expression with both recording 3-fold increased expression respectively. These associations suggest cytoplasmic CD44 staining is associated with higher grade breast cancer and thus may be proposed as a substitute for grading tumors where morphology is inconclusive. It may also be valuable if a decision needs to be made to treat a patient aggressively or otherwise based on equivocal Ki67 results or Grading/ staging. Although other parameters of tumour aggression such as lymph node involvement, Vascular invasion, Nottingham Prognostic Index, and triple negative status did not have significant association with CD44 expression, there is some evidence of correlation from this study. About 3-fold increase in CD44 expression was seen in tumours with increased mitotic index and a 2-fold increase was seen in tumours with lymph node involvement. However, in contrast with CD24, there was reduced expression of CD44 in triple negative breast tumours in our cohort likewise a reduced expression in higher stage clinical pathologic staged cancers (stage III). There were no significant associations with ER, PR and Her2 receptor status in contrast to Iris et al’s study on invasive ductal carcinoma of no special type which had significant associations with both CD24 and CD44.\textsuperscript{21} Invasive colloid carcinoma was the only histologic type that had an association with reduced CD44 expression (about 22-fold decrease in expression).

Similarly, the absence of either CD44 and CD24 expression was also associated with some features of tumour aggression and poor prognosis comparable to Giatromanolaki et al’s study.\textsuperscript{13} Tumours with CD44\textsuperscript{-}CD24\textsuperscript{-}/low phenotype were 10 times more likely to have a mitotic count \(\geq 10\) and a 7-8 times likelihood of having a poor NPI >5.41.

In keeping with Ahmed et al’s study\textsuperscript{16}, CD44\textsuperscript{+}CD24\textsuperscript{+} was the most occurring combination phenotype (76%) however, a low CD44\textsuperscript{+}CD24\textsuperscript{-}/low phenotype expression (6.1%) was recorded in their cohort as opposed to 15% in this current study. Their cohort rather expressed higher CD44\textsuperscript{-}CD24\textsuperscript{+} phenotype (31.5\% vs 5.6\%).\textsuperscript{16} This disparity may be as a result of different molecular signatures between African and Caucasian breast cancers underlying the racial disparity in tumour prognosis, aggressiveness and clinical outcomes favoring the later. Their study was on a larger series of early primary invasive breast carcinoma (1046) as opposed to the more heterogenous and smaller cohort of advance breast carcinoma (222) in this current study. These factors may also explain the difference in the phenotypic expressions.

This study corroborates other studies that reported the involvement of CD44\textsuperscript{+}CD24\textsuperscript{-}/low phenotype in tumour aggressiveness and poor prognosis.\textsuperscript{12,13,21,22} Its increased expression was significantly associated with higher tumour grade and higher clinical prognostic staging. Ahmed et al/ and Mylona et al/ however had the exact opposite conclusion with CD44\textsuperscript{+}CD24\textsuperscript{-}/low cancers showing favourable outcomes.\textsuperscript{16,23} Several studies have already linked the CD44\textsuperscript{+}CD24\textsuperscript{-}/low phenotype to triple negative breast cancer\textsuperscript{6,12-14,20,24-26} and hence it is not surprising that our cohort with a high triple negative prevalence records high CD44\textsuperscript{+}CD24\textsuperscript{-}/low. This breast cancer stem cell marker may be related to tumour aggression in our cohort.
despite its non-association with lymph node involvement. The high tumour aggressiveness of our cohort may favour hematological dissemination rather than lymphatic spread explaining this lymph node non-association.\textsuperscript{21}

Conversely, the presence of the $\text{CD44}^{+}\text{CD24}^{+}$ phenotype was associated with good prognosis and less tumour aggression a finding contrary to an earlier Asian study\textsuperscript{12}. Our study reported a significant inverse association existing between high $\text{CD44}^{+}\text{CD24}^{+}$ expression and parameters such as tumour grade, mitotic count and clinical prognostic staging. Chen \textit{et al} however had no association with any of the clinicopathological parameters\textsuperscript{12}.

$\text{CD44}^{-}\text{CD24}^{+}$ phenotype on the other hand did not have any association with the clinicopathological features in keeping with Chen \textit{et al}\textsuperscript{12}. Ahmed \textit{et al} however recorded positive association between tumour grade, Nottingham prognostic index and $\text{CD44}^{+}\text{CD24}^{+}$ phenotype.\textsuperscript{16} The combination phenotypes similarly did not show any significant association with the hormone receptor status.

**Conclusion**

$\text{CD44}^{+}\text{CD24}^{-/\text{low}}$ stem cell marker is associated with poor tumour prognosis, and aggressiveness and may be partly responsible for the inherent African breast cancer aggressiveness. This study corroborates the clinicopathological significance and prognostic value of the putative stem cell $\text{CD44}^{+}\text{CD24}^{-/\text{low}}$ in breast cancer. It is to be best of our knowledge the first study of $\text{CD44}^{+}\text{CD24}^{-/\text{low}}$ in breast cancer. It is recommended that future studies look at the association between $\text{CD44}^{+}\text{CD24}^{-/\text{low}}$ and clinical outcomes such as Disease-Free Survival (DFS), and Overall Survival (OS) in African populations.

**Declarations**

**ACKNOWLEDGEMENT**: We thank the University of Nottingham, Division of Cancer Stem Cell, for provision of laboratory and equipments for this work. We thank Commonwealth Scholarship Commission for the offer of Split-site commonwealth scholarship to undertake the project. Special thanks to Chris Nolan and Holly Nicholls for their immense technical support in the project.

**ETHICAL CONSIDERATION**

This article does not contain any studies with human participants or animals by any of the authors. Archival blocks were used with no contact with human participants.

**ETHICAL STATEMENT**

This study was approved by Ethical Review Committee of the Cape Coast Teaching Hospital with review number CCTHERC/EC/2021/004.

**CONSENT FOR PUBLICATION**
‘Not applicable’

AVAILABILITY OF DATA

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interests.

FUNDING

Commonwealth Scholarship Commission offered a split-site PhD scholarship to corresponding author to undertake this research. There has been no other financial support for other authors for this work that could have influenced its outcome.

AUTHOR CONTRIBUTIONS

EG: laboratory work, writing the manuscript, data analysis and interpretation. LA: reviewing the manuscript. PKA and LDK: contributed by double scoring and reviewing the manuscript. MST: Laboratory work and reviewing the manuscript. GAR: reviewing the manuscript. AJ: reviewing the manuscript. WO: reviewing the manuscript. AG: reviewing the manuscript.

References

1. Martin DN, Boersma BJ, Yi M, et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. *PLoS One.* 2009;4(2):e4531.

2. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. *Cancer.* 2007;110(4):876-884.

3. Amadori D, Serra P, Bravaccini S, et al. Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations. *Breast cancer research and treatment.* 2014;145(1):177-183.

4. Jiagge E, Chitale D, Newman LA. Triple-Negative Breast Cancer, Stem Cells, and African Ancestry. *The American Journal of Pathology.* 2018;188(2):271-279.

5. Schwartz T, Stark A, Pang J, et al. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. *Cancer.* 2013;119(3):488-494.

6. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. *Br J Cancer.* 2010;102(2):369-375.
7. Der EM, Gyasi RK, Tettey Y, et al. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience. *Breast J.* 2015;21(6):627-633.

8. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. *Critical reviews in oncology/hematology.* 2010;76(1):44-52.

9. Jiagge E, Jibril AS, Chitale D, et al. Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer. *Annals of surgical oncology.* 2016;23(12):3843-3849.

10. Henson DE, Chu KC, Levine PH. Histologic grade, stage, and survival in breast carcinoma: comparison of African American and Caucasian women. *Cancer.* 2003;98(5):908-917.

11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America.* 2003;100(7):3983-3988.

12. Chen Y, Song J, Jiang Y, Yu C, Ma Z. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. *International journal of clinical and experimental pathology.* 2015;8(9):11287-11295.

13. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients. *Medical oncology (Northwood, London, England).* 2011;28(3):745-752.

14. Klu J, Schefold JC, Klose K, et al. CD44(+)CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. *Hum Pathol.* 2012;43(3):364-373.

15. Hoon Tan P, Ellis I, Allison K, et al. The 2019 WHO classification of tumours of the breast. *Histopathology.* 2020.

16. Ahmed MA, Aleskandarany MA, Rakha EA, et al. A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. *Breast cancer research and treatment.* 2012;133(3):979-995.

17. Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. *Annals of surgical oncology.* 2009;16(10):2705-2710.

18. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. *J Natl Cancer Inst.* 1994;86(9):705-712.

19. Kristiansen G, Winzer K-J, Mayordomo E, et al. CD24 Expression Is a New Prognostic Marker in Breast Cancer. 2003;9(13):4906-4913.

20. Kapucuoglu N, Bozkurt KK, Baspinar S, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. *Pathology, research and practice.* 2015;211(10):740-747.

21. Iris R, Ana Paula Martins S, Rubens Silveira L, et al. Cancer stem cell markers ALDH1 and CD44+/CD24− phenotype and their prognosis impact in invasive ductal carcinoma. *European Journal of Histochemistry.* 2018;62:2943.
22. Lin Y, Zhong Y, Guan H, Zhang X, Sun Q. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. *Journal of experimental & clinical cancer research : CR.* 2012;31:59.

23. Mylona E, Giannopoulou I, Fasomytakis E, et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. *Hum Pathol.* 2008;39(7):1096-1102.

24. Chekhun SV, Zadvorny TV, Tymovska YO, Anikusko MF, Novak OE, Polishchuk LZ. capital ES, CyrillicD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes. *Experimental oncology.* 2015;37(1):58-63.

25. Gudadze M, Kankava Q, Mariamidze A, Burkadze G. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast. *Georgian medical news.* 2014(228):81-87.

26. Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. *J Clin Pathol.* 2011;64(11):937-946.